TL;DR: Sermorelin is a synthetic 29-amino acid analog of growth hormone-releasing hormone (GHRH), specifically the biologically active N-terminal fragment designated GHRH(1-29)-NH2. It acts as a full agonist at the pituitary GHRH receptor, stimulating endogenous growth hormone secretion via a cAMP-mediated pathway. Sermorelin was formerly FDA-approved (as Geref) for GH-deficiency diagnostic testing and as a pediatric therapeutic, but the branded product was voluntarily withdrawn from the U.S. market and is no longer an approved drug. It is now most commonly encountered as a compounded preparation. Educational and research reference only, not a protocol guide or medical advice.
Research-Use Disclaimer: This article is for educational and research reference purposes only. Sermorelin is not currently approved by the FDA for human use as a marketed drug. This content does not constitute medical advice, does not recommend or endorse human administration of any compound, and does not describe protocols for personal use. All study findings referenced below are from published scientific literature. For adults 21+ with a research interest only.
What Is Sermorelin? Definition and Structure
Sermorelin, also written as sermorelin acetate or GHRH(1-29)-NH2, is a synthetic peptide analog comprising the first 29 amino acids of endogenous human growth hormone-releasing hormone (GHRH), the 44-residue hypothalamic signaling peptide that governs pulsatile GH secretion from the anterior pituitary. The GHRH(1-29) fragment retains full biological activity at the GHRH receptor; the remaining C-terminal residues (30–44) of native GHRH contribute structural stability but are not required for receptor binding or activation.
Its amino acid sequence is: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2. The C-terminal amide group (-NH2) is a synthetic modification that enhances metabolic stability relative to unmodified peptide chains.
How Does Sermorelin Work? The GHRH Receptor Mechanism
Sermorelin’s mechanism of action is well-characterized in the published pharmacology literature. Unlike synthetic GH secretagogues (such as ipamorelin or GHRP-6) which act at the ghrelin/GHS receptor, sermorelin acts exclusively through the pituitary-type GHRH receptor (pGHRH-R), a G protein-coupled receptor (GPCR) expressed on somatotroph cells in the anterior pituitary gland.
How does sermorelin stimulate GH secretion at the cellular level?
Sermorelin binds the GHRH receptor on pituitary somatotrophs, activating adenylyl cyclase and elevating intracellular cyclic adenosine monophosphate (cAMP) concentrations. The resulting cAMP surge activates protein kinase A (PKA), which in turn promotes calcium influx and triggers the exocytotic release of stored GH granules. This is the same molecular cascade used by endogenous GHRH, sermorelin is a full agonist, not a partial agonist or modulator.
Based on articles retrieved from PubMed, a 1989 study by Cheng et al., published in Endocrinology, investigated GHRH(1-29) ([N-Ac-Tyr1, D-Arg2]GRF-1-29 used as antagonist reference) in rat primary pituitary cell culture, demonstrating that GRF (GHRH) increased intracellular cAMP by approximately 3-fold and that GH release was dose-dependent and time-dependent. A 1996 study by Wu et al., published in the Journal of Endocrinology, further characterized the cAMP pathway, showing that pharmacological blockade of adenylyl cyclase (with MDL 12, 330A) prevented both cAMP accumulation and GH release in response to GHRH, while cAMP antagonists (Rp-cAMP) also blocked GH secretion, confirming that the cAMP pathway is obligate for GHRH receptor-mediated GH release, not merely modulatory.
What distinguishes the GHRH receptor pathway from other GH secretagogue mechanisms?
The distinction matters for understanding sermorelin’s mechanism precisely. The GHRH receptor pathway (sermorelin’s target) primarily operates through cAMP elevation and is somatostatin-sensitive, meaning somatostatin, the hypothalamic GH-inhibiting hormone, can suppress the GHRH-stimulated GH pulse at the pituitary level. This is in contrast to ghrelin-type secretagogues (GHRP-6, ipamorelin), which operate through a distinct receptor (GHS-R) and a largely cAMP-independent calcium-mobilization pathway. The two pathways are synergistic when combined, a pharmacological property exploited in research on combined secretagogue protocols.
Sermorelin’s History: From Hypothalamic Science to FDA Approval and Discontinuation
What is the origin of GHRH science and how did sermorelin emerge from it?
The discovery of endogenous GHRH was a landmark in neuroendocrinology. As documented in a comprehensive 1986 review by Grossman, Savage, and Besser in Clinics in Endocrinology and Metabolism, human GHRH was originally extracted from pancreatic tumors in two patients with acromegaly and was found to consist of a 44-residue amidated peptide along with C-terminally shortened derivatives, the latter establishing that the N-terminal fragment retained full activity. The 1986 review noted that “analogues of GHRH are useful in the investigation of the hypothalamopituitary axis, and may be important in the therapy of short stature.” Sermorelin, the GHRH(1-29) fragment, emerged from this early characterization as the shortest fully active sequence, and became the primary research tool and eventual clinical formulation.
What did early clinical research on GHRH(1-29) in GH-deficient children show?
Based on articles retrieved from PubMed, the clinical evidence for GHRH(1-29) in pediatric GH deficiency was established across several trials in the 1980s and early 1990s. A pivotal 1987 study by Ross et al. in The Lancet treated 18 prepubertal GH-deficient children with twice-daily subcutaneous injections of GHRH(1-29)-NH2, finding that 8 of the 18 children showed a worthwhile response defined as an increase in height velocity of greater than 2 cm/yr, with a range of 2.7–11.2 cm/yr among responders, and that this increase was maintained over 6–18 months of treatment. The study also noted that a pretreatment peak serum GH response above 30 mU/l during an intravenous GHRH test was predictive of a good growth response.
A 1993 randomized controlled trial by Chen et al., published in Acta Paediatrica Supplement, compared two doses of GHRH(1-29)-NH2 to GH therapy in 60 children with hypothalamic-origin GH deficiency. Mean height velocities at 6 months were 9.2 and 9.3 cm/year for the two GHRH dose groups versus 14.6 cm/year for the GH group, demonstrating that while GHRH(1-29) produced meaningful growth acceleration, standard GH therapy was statistically superior. The authors concluded that continuous-infusion GHRH(1-29) was unlikely to be as effective as GH for promoting growth in GH-deficient children.
A 1997 multicenter study by Ogilvy-Stuart et al. in Clinical Endocrinology extended this to children with radiation-induced GH deficiency, reporting a significant increase in height velocity from 3.3 cm/year before treatment to 6.0 cm/year after one year of GHRH(1-29)-NH2 (P = 0.004), with no adverse changes in biochemical or hormonal analyses. Following the study year, GH therapy produced 7.5 cm/year, again higher, though not directly comparable given different populations.
What Was Sermorelin’s FDA-Approved Status (Geref) and Why Was It Discontinued?
Sermorelin was FDA-approved in the United States under the brand name Geref (manufactured by Serono Laboratories). The approved indications included:
- Diagnostic use: evaluation of the ability of the somatotrophs of the anterior pituitary gland to release GH (the “sermorelin stimulation test”), used to evaluate children with suspected GH deficiency
- Therapeutic use: treatment of idiopathic GH deficiency in children with growth failure
Geref was voluntarily withdrawn from the U.S. market by the manufacturer, not removed for safety or efficacy reasons. The withdrawal was a business decision by Serono; this distinction is important because voluntary withdrawal does not carry the same meaning as FDA-initiated market removal. As a consequence, sermorelin no longer has an active, FDA-approved New Drug Application (NDA) in the United States and is not currently a legally marketed pharmaceutical drug.
Following the withdrawal of Geref, sermorelin has been most commonly encountered as a compounded preparation prepared by 503A/503B compounding pharmacies. The regulatory landscape for compounded peptides, including sermorelin, has been subject to ongoing FDA guidance changes, particularly following the Compounding Quality Act and subsequent FDA communications on bulk drug substances. Researchers and clinicians should consult current FDA guidance on compounded peptide status directly, as this area of regulation has continued to evolve through 2025 and beyond.
What Is Sermorelin’s Evidence Tier? An Honest Assessment
Because sermorelin was a formerly approved therapeutic compound, its evidence profile differs meaningfully from most research peptides that have only preclinical data. The table below summarizes the evidence landscape:
| Evidence Level | Status for Sermorelin / GHRH(1-29) (as of 2026) |
|---|---|
| Human randomized controlled trials | Present, pediatric GH deficiency (diagnostic and growth-promotion contexts); limited adult data |
| Peer-reviewed mechanistic studies | Well-characterized, GHRH receptor / cAMP pathway pharmacology established in pituitary cell models |
| Diagnostic use history | Established, formerly used as the “sermorelin stimulation test” for pediatric GH axis evaluation |
| FDA approval status | Formerly approved (Geref); voluntarily withdrawn; not currently an approved marketed drug |
| Compounded availability | Available through 503A/503B pharmacies, subject to evolving FDA guidance on compounded peptides |
The critical context: Sermorelin’s former approval status means it has a richer human evidence base than many research peptides. However, that history applies specifically to pediatric GH-deficiency indications under an approved protocol, it does not generalize to all proposed uses. The evidence should be read in the context for which it was generated: primarily pediatric growth hormone axis evaluation and GH-deficiency therapy in children with documented hypothalamic-origin deficiency.
How Does Sermorelin Compare to Other GHRH-Family Analogs?
Understanding sermorelin’s place in the GHRH analog landscape requires distinguishing it from structurally related compounds:
- CJC-1295: A modified GHRH(1-29) analog with a Drug Affinity Complex (DAC) modification that extends its half-life by binding endogenous albumin. CJC-1295 was studied for its prolonged GH-releasing profile; sermorelin has a much shorter active half-life.
- Tesamorelin: A GHRH analog (trans-3-hexenoic acid modification to native GHRH) that received FDA approval (as Egrifta) for HIV-associated lipodystrophy, the only GHRH analog currently holding an active FDA approval in the United States as of 2026.
- Native GHRH (1-44): The full-length endogenous form; sermorelin retains the biologically active N-terminal 29 residues with equivalent receptor activity but shorter metabolic half-life than the full sequence.
Based on research retrieved from PubMed, Schally et al. published work in 2018 in Proceedings of the National Academy of Sciences characterizing GHRH agonist activity, demonstrating that GHRH agonists act on pituitary GHRH receptor splice variants (pGHRH-R and SV1) and that receptor down-regulation is a documented response to sustained agonist exposure, a pharmacological consideration relevant to any discussion of the GHRH agonist class.
Frequently Asked Questions About Sermorelin
What is sermorelin and how does it differ from GHRH?
Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) comprising the biologically active N-terminal 29 amino acids of the native 44-residue hypothalamic peptide, hence the designation GHRH(1-29)-NH2. It binds the pituitary GHRH receptor and stimulates endogenous growth hormone secretion through the same cAMP-mediated pathway as full-length GHRH, but with a shorter sequence that retains full agonist activity. The C-terminal amide group improves metabolic stability compared to unmodified fragments.
Was sermorelin ever FDA approved?
Yes, with important regulatory nuance. Sermorelin was previously FDA-approved under the brand name Geref (Serono) for diagnostic evaluation of pituitary GH-secretory capacity and for treatment of idiopathic GH deficiency in children. The branded product was voluntarily withdrawn from the U.S. market by the manufacturer, not removed for safety or efficacy violations. Sermorelin is therefore not currently an FDA-approved drug, and is most often encountered today as a compounded preparation under evolving regulatory frameworks.
What does the research show about sermorelin stimulating GH release?
Based on articles retrieved from PubMed, sermorelin (GHRH 1-29) stimulates GH release from pituitary somatotrophs by binding the GHRH receptor and elevating intracellular cAMP in a dose-dependent manner. Clinical studies in GH-deficient children published in The Lancet (Ross et al., 1987) documented meaningful increases in height velocity, 8 of 18 treated children increased height velocity by more than 2 cm/year. A 1993 randomized trial (Chen et al.) showed GHRH(1-29) produced height velocity of approximately 9 cm/year versus 14.6 cm/year for GH therapy, indicating efficacy but inferiority to direct GH replacement in that population.
What is sermorelin’s current regulatory and compounding status in the United States?
Sermorelin does not hold an active FDA NDA; the branded Geref was voluntarily discontinued. Compounding pharmacies have prepared sermorelin under Section 503A/503B of federal law, but the regulatory landscape governing compounded peptides has shifted significantly since 2020, with the FDA issuing updated guidance on bulk drug substances. Researchers and clinicians should consult current FDA guidance on compounded peptide status directly; this area of regulation continues to evolve.
Research use only. Not intended for human use. Sermorelin is not currently an FDA-approved drug; the branded product Geref was voluntarily withdrawn from the U.S. market. This article documents published scientific literature and regulatory history for educational and reference purposes and is not medical advice; nothing here is intended to diagnose, treat, cure, or prevent any disease, or to recommend human use of any compound. All citations link to primary sources, read them in full. Must be 21+.